The induction of p75NTR by entinostat occurred within a concentration range (0.1–1.0 μM) which correlated with the reported micromolar potency of the drug in inhibiting HDAC activity [31] and with the plasma concentrations that were required to produce anti-cancer effects in clinical trials [26]. Here, HDAC9 is linked to cancer.